AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Novo Nordisk's Levemir on track in US market.
(From Chemical Business NewsBase - Dagbladet Borsen)
Novo Nordisk had targeted a 5-10% share of the US market for long acting basal insulin analogues and after 1 year on the market Levemir has achieved a 6-7% share. The company believes therefore that it is on track to achieve its goal. Sales of Levemir totalled DKR 1.4 bn in 2006 but Novo Nordisk did not wish to specify what the European and US contributions to this figure were. The consensus forecast of analysts was DKR 1376 M. At the end of Nov 2006 Levemir's share of the European market for basal analogues was over 22%. The only competition in this sector is Sanofi-Aventis' Lantus. …
-
- Novo Nordisk prevails in Sanofi-Aventis challenge to Levemir - up to 24 hours...
-
News wire article from: Chemical Business Newsbase
June 27, 2006
700+ words
-
- Novo Nordisk receives EU approval of Levemir, new long-acting insulin analogue.
-
News wire article from: Asia Africa Intelligence Wire
June 4, 2004
700+ words
-
- Novo Nordisk receives positive opinion on Levemir (insulin detemir) from EU...
-
News wire article from: Asia Africa Intelligence Wire
February 27, 2004
700+ words
-
- New pressure on Novo Nordisk's Levemir in US.
-
News wire article from: Chemical Business Newsbase
December 18, 2006
700+ words
-
- Novo Nordisk receives US approval of Levemir and becomes the first company...
-
News wire article from: Asia Africa Intelligence Wire
June 17, 2005
700+ words
